Cytoki Pharma Announces First Patient Dosed in Phase 2 Study of CK-0045 in Obesity and Type 2 Diabetes
Hand-out
Press Releases
Cytoki Pharma  
November 4, 2024

Cytoki Pharma Announces First Patient Dosed in Phase 2 Study of CK-0045 in Obesity and Type 2 Diabetes

The Phase 2 study will evaluate the efficacy, safety and tolerability of the company's lead lipidated IL-22 analogue, CK-0045, in patients with obesity and type 2 diabetes

avatar profile Olean Times Herald

Olean Times Herald


Local & Social